首页> 美国卫生研究院文献>Dermatology and Therapy >Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
【2h】

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial

机译:Dupilumab通过良好控制的几周测量的具有中度至严重的特征性皮炎的成年人中的长期疾病控制:来自自由AD Chronos临床试验的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Median percentage of well-controlled weeks (weeks 1–52) by treatment group. q2w, every 2 weeks; TCS, topical corticosteroids. Patients using rescue medication were considered non-responders, and missing values were handled using the last observation carried forward method. Imputed patients: placebo = 94/315; dupilumab 300 mg q2w = 49/110
机译:治疗组的受控周(周1-52周)中位数百分比。 Q2W,每2周; TCS,局部皮质类固醇。使用救援药物的患者被认为是非响应者,并且使用最后的观察结果处理缺失的值载发方法。占患者:安慰剂= 94/315; Dupilumab 300 mg Q2w = 49/110

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号